{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:22:03Z","timestamp":1777929723362,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,20]],"date-time":"2009-04-20T00:00:00Z","timestamp":1240185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,20]],"date-time":"2009-04-20T00:00:00Z","timestamp":1240185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Onkologie"],"abstract":"<jats:p>Die Werte f\u00fcr die Peptidhormone LH, FSH, TSH, Prolaktin, \u03b2-HCG und Parathormone schwanken erheblich bei Patienten mit urogenitalen Tumoren. \u03b2-HCG ist nur beim Chorionkarzinom, beim Hodenteratom und beim embryonalen Hodenkarzinom erh\u00f6ht und steigert die Sekretion von Prolaktin. Serum-TSH und Prolaktin sind beim Nierenkarzinom auff\u00e4llig ver\u00e4ndert. Nach Nephrektomie bei fortgeschrittenem Tumorstadium persistiert der pathologisch erh\u00f6hte TSH-Gehalt, w\u00e4hrend sich h\u00e4ufiger emiedrigte PTH-Werte in dieser Gruppe nach-weisen lassen. Beim Blasenkarzinom weichen LH und Prolaktin in Abh\u00e4ngigkeit vom Tumorstadium von der Norm ab. Prostataadenom und Karzinom zeigen \u00e4hnliche Werte f\u00fcr die Peptidhormone. Die \u00d6strogentherapie ver\u00e4ndert den Serum TSH-, Prolaktin- und den LH-Gehalt. Die Konzentration der Peptidhormone wird nicht allein durch die endokrine Aktivit\u00e4t des Tumors, hormoninaktive Peptidanalogien, altersbedingte Verschiebungen, sondern auch durch die Art der Therapie beeinflu\u00dft.<\/jats:p>","DOI":"10.1159\/000214908","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T10:40:22Z","timestamp":1240396822000},"page":"188-192","source":"Crossref","is-referenced-by-count":1,"title":["Peptidhormone LH, FSH, TSH, Prolaktin, \u03b2-HCG und PTH bei Patienten mit urogenitalen Tumoren"],"prefix":"10.1159","author":[{"given":"Udo","family":"Dunzendorfer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dusan","family":"Drahovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinrich","family":"Schmidt-Gayk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,4,20]]},"container-title":["Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/214908","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000214908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:51:39Z","timestamp":1777679499000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000214908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,20]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000214908","archive":["Portico"],"relation":{},"ISSN":["0378-584X","1423-0240"],"issn-type":[{"value":"0378-584X","type":"print"},{"value":"1423-0240","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,20]]}}}